financetom
Business
financetom
/
Business
/
Primis Financial Q3 net income jumps on higher net interest margin, expects profitability growth in 2026
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Primis Financial Q3 net income jumps on higher net interest margin, expects profitability growth in 2026
Oct 23, 2025 2:39 PM

Overview

* Primis Financial ( FRST ) Q3 net income rises to $7 mln, showing substantial growth from 2024

* Company's net interest margin improves to 3.18% in Q3 2025 from 2.97% in Q3 2024

* Primis Financial ( FRST ) declares quarterly cash dividend of $0.10 per share

Outlook

* Primis expects further net interest margin improvement in Q4 2025 due to rate cuts

* Company anticipates profitability growth into 2026 driven by business momentum

* Primis plans to enhance V1BE service for licensing to other banks

Result Drivers

* NET INTEREST MARGIN - Improved net interest margin driven by favorable deposit pricing and rebuilding of earning asset levels

* OPERATING LEVERAGE - Revenue growth with minimal increase in operating expenses improved performance

* MORTGAGE WAREHOUSE GROWTH - Expansion of mortgage warehouse lending significantly increased loan balances and net interest income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $0.28

Q3 Net $7 mln

Income

Q3 Net $29 mln

Interest

Income

Q3 $0.10

Dividend

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy."

* Wall Street's median 12-month price target for Primis Financial Corp ( FRST ) is $13.63, about 27.3% above its October 21 closing price of $9.90

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Anglo Teck agreement binds assets of 'extraordinary value', says head of Chile's Codelco
Anglo Teck agreement binds assets of 'extraordinary value', says head of Chile's Codelco
Sep 9, 2025
SANTIAGO, Sept 9 (Reuters) - The agreement between Anglo American and Teck brings together assets of extraordinary value, the chairman of Chile's state-run copper producer Codelco, Maximo Pacheco, told Reuters on Tuesday. London-listed miner Anglo American and Canada's Teck Resources ( TECK ) announced their merger earlier on Tuesday, in what would be the biggest mining sector M&A deal in...
Walmart to launch first stores in Africa by year-end
Walmart to launch first stores in Africa by year-end
Sep 9, 2025
By Siyanda Mthethwa JOHANNESBURG (Reuters) -U.S. retailer Walmart ( WMT ) will launch its first branded stores in South Africa this year, it said on Tuesday. The move by Walmart ( WMT ), which already owns South African retail group Massmart, places it in direct competition with established domestic retailers including market leader Shoprite, Woolworths and Pick n Pay. Online,...
Sector Update: Consumer
Sector Update: Consumer
Sep 9, 2025
08:53 AM EDT, 09/09/2025 (MT Newswires) -- Consumer stocks were mixed pre-bell Tuesday, with the Consumer Staples Select Sector SPDR Fund (XLP) down 0.3% and the Consumer Discretionary Select Sector SPDR Fund (XLY) 0.1% higher. Designer Brands ( DBI ) shares were down more than 1% after the company reported a decline in fiscal Q2 net sales and said it...
Xilio Therapeutics Starts Phase 2 Trial for Potential Anti-Tumor Monotherapy, Achieves $17.5 Million Development Milestone Under License Deal With Gilead
Xilio Therapeutics Starts Phase 2 Trial for Potential Anti-Tumor Monotherapy, Achieves $17.5 Million Development Milestone Under License Deal With Gilead
Sep 9, 2025
08:53 AM EDT, 09/09/2025 (MT Newswires) -- Xilio Therapeutics ( XLO ) said Tuesday it started phase 2 of an ongoing phase 1/2 clinical trial assessing efarindodekin alfa, a potential monotherapy for patients with certain advanced solid tumors. The company said that in connection with beginning of phase 2, it achieved a $17.5 million development milestone under its exclusive global...
Copyright 2023-2026 - www.financetom.com All Rights Reserved